{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T14:43:37Z","timestamp":1788273817092,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:00:00Z","timestamp":1752710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Internal grants program of Pavol Jozef \u0160af\u00e1rik University","award":["VVGS-2023-2548"],"award-info":[{"award-number":["VVGS-2023-2548"]}]},{"name":"Grant Agency of the Ministry of the Education, Science, Research and Sport of the Slovak Republic","award":["KEGA 009UPJ\u0160-4\/2023"],"award-info":[{"award-number":["KEGA 009UPJ\u0160-4\/2023"]}]},{"name":"Grant Agency of the Ministry of the Education, Science, Research and Sport of the Slovak Republic","award":["VEGA 1\/0653\/19"],"award-info":[{"award-number":["VEGA 1\/0653\/19"]}]},{"name":"Grant Agency of the Ministry of the Education, Science, Research and Sport of the Slovak Republic","award":["1\/0513\/21"],"award-info":[{"award-number":["1\/0513\/21"]}]},{"name":"Grant Agency of the Ministry of the Education, Science, Research and Sport of the Slovak Republic","award":["1\/0539\/21"],"award-info":[{"award-number":["1\/0539\/21"]}]},{"name":"Grant Agency of the Ministry of the Education, Science, Research and Sport of the Slovak Republic","award":["1\/0498\/23"],"award-info":[{"award-number":["1\/0498\/23"]}]},{"name":"Operational Programme Integrated Infrastructure, funded by the ERDF","award":["ITMS2014+: 313011V455"],"award-info":[{"award-number":["ITMS2014+: 313011V455"]}]},{"name":"Operational Programme Research & Innovation, funded by the ERDF","award":["k\u00f3d ITMS2014 + 313011D103"],"award-info":[{"award-number":["k\u00f3d ITMS2014 + 313011D103"]}]},{"DOI":"10.13039\/100030974","name":"Pavol Jozef \u0160af\u00e1rik University in Ko\u0161ice","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100030974","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Cyanobacteria have long attracted scientific interest through their potential application in the development of new therapeutic approaches, particularly those related to the treatment of cancer. In this study, the antiproliferative effects of <jats:italic>Nostoc commune<\/jats:italic> extract (NOS) and the cyanobacterial compound scytonemin (SCY) were evaluated against a variety of in vitro cancer models, including cervix, colon, breast, lung, and leukemia cell lines, using resazurin assays. Both of the studied compounds were found to have inhibited metabolic activity in a dose-dependent manner, with IC<jats:sub>50<\/jats:sub> values ranging from 60.5 to 462.0\u00a0\u00b5M for SCY and 157.0 to 740.3\u00a0\u00b5M for NOS. SCY displayed higher levels of inhibitory activity than NOS against all of the tested cancer models, but was particularly effective against HL-60 and Jurkat leukemia cells, with IC<jats:sub>50<\/jats:sub> values recorded as 60.5\u00a0\u00b5M and 88.2\u00a0\u00b5M, respectively. However in contrast, the two compounds exhibited significantly lower levels of inhibition against non-cancerous MCF-10A and BJ-5ta cells. Flow cytometry studies of leukemia cells treated with SCY revealed that the compound had effectively inhibited cell proliferation over prolonged periods; HL-60 cells displayed G1 phase arrest which lasted for 48\u00a0h, while an accumulated G0\/G1 sub-population was detected in Jurkat cells, as indicator of apoptosis. Further analysis of cells treated with SCY observed reduced levels of Rb protein and an increase in p21 expression in both HL-60 and Jurkat cell lines. Apoptotic markers such as phosphatidylserine externalization were observed, and mitochondrial dysfunction characterized by the dissipation of mitochondrial membrane potential was also detected. SCY activated the mitochondrial apoptotic pathway, inducing cytochrome <jats:italic>c<\/jats:italic> release and subsequent caspase-9, -3, and -7 activation. Finally, PARP cleavage, a typical marker of apoptosis, was identified in both leukemia cell lines following treatment with SCY. The findings suggest that SCY induces apoptosis in leukemia cells through the activation of the mitochondrial pathway, highlighting its potential for development as a future anti-cancer agent.<\/jats:p>","DOI":"10.1007\/s12032-025-02890-3","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T02:34:55Z","timestamp":1752719695000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Nostoc commune-derived scytonemin induced mitochondrial cell death in leukemia models"],"prefix":"10.1007","volume":"42","author":[{"given":"Simona","family":"Zilakova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Gavurova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2109-1824","authenticated-orcid":false,"given":"Dominika","family":"Sebova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9517-158X","authenticated-orcid":false,"given":"Michal","family":"Goga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9765-4662","authenticated-orcid":false,"given":"Martin","family":"Backor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktoria","family":"Medvecova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3311-308X","authenticated-orcid":false,"given":"Dajana","family":"Kecsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2454-5799","authenticated-orcid":false,"given":"Martin","family":"Kello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,17]]},"reference":[{"issue":"2","key":"2890_CR1","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41375-024-02452-y","volume":"39","author":"DS Daltveit","year":"2025","unstructured":"Daltveit DS, Morgan E, Colombet M, Steliarova-Foucher E, Bendahhou K, Marcos-Gragera R, Rongshou Z, Smith A, Wei H, Soerjomataram I. Global patterns of leukemia by subtype, age, and sex in 185 countries in 2022. Leukemia. 2025;39(2):412\u20139. https:\/\/doi.org\/10.1038\/s41375-024-02452-y.","journal-title":"Leukemia"},{"key":"2890_CR2","doi-asserted-by":"publisher","first-page":"100040","DOI":"10.1016\/j.oor.2023.100040","volume":"6","author":"BS Mali","year":"2023","unstructured":"Mali BS. Cancer treatment: role of natural products. Time to have a serious rethink. Oral Oncol Rep. 2023;6:100040. https:\/\/doi.org\/10.1016\/j.oor.2023.100040.","journal-title":"Oral Oncol Rep"},{"key":"2890_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12010201","author":"P Chunarkar-Patil","year":"2024","unstructured":"Chunarkar-Patil P, Kaleem M, Mishra R, Ray S, Ahmad A, Verma D, Bhayye S, Dubey R, Singh HN, Kumar S. Anticancer drug discovery based on natural products: from computational approaches to clinical studies. Biomedicines. 2024. https:\/\/doi.org\/10.3390\/biomedicines12010201.","journal-title":"Biomedicines"},{"issue":"4","key":"2890_CR4","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1021\/acschembio.0c00139","volume":"15","author":"T Grkovic","year":"2020","unstructured":"Grkovic T, Akee RK, Thornburg CC, Trinh SK, Britt JR, Harris MJ, Evans JR, Kang U, Ensel S, Henrich CJ, Gustafson KR, Schneider JP, O\u2019Keefe BR. National Cancer Institute (NCI) program for natural products discovery: rapid isolation and identification of biologically active natural products from the NCI Prefractionated Library. ACS Chem Biol. 2020;15(4):1104\u201314. https:\/\/doi.org\/10.1021\/acschembio.0c00139.","journal-title":"ACS Chem Biol"},{"issue":"19","key":"2890_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e37851","volume":"10","author":"MT Darwich-Cedeno","year":"2024","unstructured":"Darwich-Cedeno MT, Montenegro-Ruiz LC, Reis M, Vasconcelos V. Colombian cyanobacteria with cytotoxic activity in cancer cell lines. Heliyon. 2024;10(19): e37851. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e37851.","journal-title":"Heliyon"},{"key":"2890_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26010247","author":"H Qamar","year":"2021","unstructured":"Qamar H, Hussain K, Soni A, Khan A, Hussain T, Chenais B. Cyanobacteria as natural therapeutics and pharmaceutical potential: role in antitumor activity and as nanovectors. Molecules. 2021. https:\/\/doi.org\/10.3390\/molecules26010247.","journal-title":"Molecules"},{"key":"2890_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17020318","author":"T Vujovic","year":"2025","unstructured":"Vujovic T, Paradzik T, Babic Brcic S, Piva R. Unlocking the therapeutic potential of algae-derived compounds in hematological malignancies. Cancers. 2025. https:\/\/doi.org\/10.3390\/cancers17020318.","journal-title":"Cancers"},{"issue":"6","key":"2890_CR8","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3390\/md23060233","volume":"23","author":"HNK Lee","year":"2025","unstructured":"Lee HNK, Kwon YR. Cyanobacterial peptides in anticancer therapy: a comprehensive review of mechanisms, clinical advances, and biotechnological innovation. Mar Drugs. 2025;23(6):233. https:\/\/doi.org\/10.3390\/md23060233.","journal-title":"Mar Drugs"},{"issue":"1922","key":"2890_CR9","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1098\/rsta.2010.0019","volume":"368","author":"T Varnali","year":"2010","unstructured":"Varnali T, Edwards HG. Ab initio calculations of scytonemin derivatives of relevance to extremophile characterization by Raman spectroscopy. Philos Trans A Math Phys Eng Sci. 2010;368(1922):3193\u2013203. https:\/\/doi.org\/10.1098\/rsta.2010.0019.","journal-title":"Philos Trans A Math Phys Eng Sci"},{"issue":"2","key":"2890_CR10","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/med.10002","volume":"22","author":"M Eggen","year":"2002","unstructured":"Eggen M, Georg GI. The cryptophycins: their synthesis and anticancer activity. Med Res Rev. 2002;22(2):85\u2013101. https:\/\/doi.org\/10.1002\/med.10002.","journal-title":"Med Res Rev"},{"issue":"4","key":"2890_CR11","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1007\/s13277-013-0764-5","volume":"34","author":"G Zhang","year":"2013","unstructured":"Zhang G, Zhang Z, Liu Z. Scytonemin inhibits cell proliferation and arrests cell cycle through downregulating Plk1 activity in multiple myeloma cells. Tumour Biol. 2013;34(4):2241\u20137. https:\/\/doi.org\/10.1007\/s13277-013-0764-5.","journal-title":"Tumour Biol"},{"key":"2890_CR12","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.fct.2013.07.016","volume":"60","author":"T Itoh","year":"2013","unstructured":"Itoh T, Tsuzuki R, Tanaka T, Ninomiya M, Yamaguchi Y, Takenaka H, Ando M, Tsukamasa Y, Koketsu M. Reduced scytonemin isolated from Nostoc commune induces autophagic cell death in human T-lymphoid cell line Jurkat cells. Food Chem Toxicol. 2013;60:76\u201382. https:\/\/doi.org\/10.1016\/j.fct.2013.07.016.","journal-title":"Food Chem Toxicol"},{"issue":"1","key":"2890_CR13","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1111\/1574-6941.12220","volume":"87","author":"RP Rastogi","year":"2014","unstructured":"Rastogi RP, Incharoensakdi A. Characterization of UV-screening compounds, mycosporine-like amino acids, and scytonemin in the cyanobacterium Lyngbya sp. CU2555. FEMS Micrbiol Ecol. 2014;87(1):244\u201356. https:\/\/doi.org\/10.1111\/1574-6941.12220.","journal-title":"FEMS Micrbiol Ecol"},{"issue":"2","key":"2890_CR14","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1111\/j.1574-6941.2011.01113.x","volume":"77","author":"EP Balskus","year":"2011","unstructured":"Balskus EP, Case RJ, Walsh CT. The biosynthesis of cyanobacterial sunscreen scytonemin in intertidal microbial mat communities. FEMS Microbiol Ecol. 2011;77(2):322\u201332. https:\/\/doi.org\/10.1111\/j.1574-6941.2011.01113.x.","journal-title":"FEMS Microbiol Ecol"},{"key":"2890_CR15","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.1007\/s10811-023-03109-6","volume":"35","author":"DVM Ru\u010dov\u00e1","year":"2023","unstructured":"Ru\u010dov\u00e1 DVM, Sovov\u00e1 VZ, Kosteck\u00e1 Z, Fren\u00e1k R, Routray D, Backor M. Photoprotective and antioxidant properties of scytonemin isolated from Antarctic cyanobacterium Nostoc commune Vaucher ex Bornet & Flahault and its potential as sunscreen ingredient. J Appl Phycol. 2023;35:2839\u201350.","journal-title":"J Appl Phycol"},{"key":"2890_CR16","doi-asserted-by":"publisher","unstructured":"Seckbach J. Algae and cyanobacteria in extreme environments. 1st ed. Dordrecht: Springer; 2007. https:\/\/doi.org\/10.1007\/978-1-4020-6112-7","DOI":"10.1007\/978-1-4020-6112-7"},{"key":"2890_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.889875","volume":"13","author":"M Romo-Gonzalez","year":"2022","unstructured":"Romo-Gonzalez M, Ijurko C, Hernandez-Hernandez A. Reactive oxygen species and metabolism in leukemia: a dangerous liaison. Front Immunol. 2022;13: 889875. https:\/\/doi.org\/10.3389\/fimmu.2022.889875.","journal-title":"Front Immunol"},{"issue":"7","key":"2890_CR18","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/nrd2803","volume":"8","author":"D Trachootham","year":"2009","unstructured":"Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov. 2009;8(7):579\u201391. https:\/\/doi.org\/10.1038\/nrd2803.","journal-title":"Nat Rev Drug Discov"},{"key":"2890_CR19","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.fct.2014.04.019","volume":"69","author":"T Itoh","year":"2014","unstructured":"Itoh T, Koketsu M, Yokota N, Touho S, Ando M, Tsukamasa Y. Reduced scytonemin isolated from Nostoc commune suppresses LPS\/IFNgamma-induced NO production in murine macrophage RAW264 cells by inducing hemeoxygenase-1 expression via the Nrf2\/ARE pathway. Food Chem Toxicol. 2014;69:330\u20138. https:\/\/doi.org\/10.1016\/j.fct.2014.04.019.","journal-title":"Food Chem Toxicol"},{"issue":"12","key":"2890_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1912","volume":"6","author":"G Loureiro","year":"2023","unstructured":"Loureiro G, Bahia DM, Lee MLM, de Souza MP, Kimura EYS, Rezende DC, Silva MCA, Chauffaille M, Yamamoto M. MAPK\/ERK and PI3K\/AKT signaling pathways are activated in adolescent and adult acute lymphoblastic leukemia. Cancer Rep (Hoboken). 2023;6(12): e1912. https:\/\/doi.org\/10.1002\/cnr2.1912.","journal-title":"Cancer Rep (Hoboken)"},{"issue":"2","key":"2890_CR21","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1124\/jpet.102.036350","volume":"303","author":"CS Stevenson","year":"2002","unstructured":"Stevenson CS, Capper EA, Roshak AK, Marquez B, Eichman C, Jackson JR, Mattern M, Gerwick WH, Jacobs RS, Marshall LA. The identification and characterization of the marine natural product scytonemin as a novel antiproliferative pharmacophore. J Pharmacol Exp Ther. 2002;303(2):858\u201366. https:\/\/doi.org\/10.1124\/jpet.102.036350.","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"2890_CR22","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.bcp.2004.02.025","volume":"68","author":"J Subhashini","year":"2004","unstructured":"Subhashini J, Mahipal SV, Reddy MC, Mallikarjuna Reddy M, Rachamallu A, Reddanna P. Molecular mechanisms in C-Phycocyanin induced apoptosis in human chronic myeloid leukemia cell line-K562. Biochem Pharmacol. 2004;68(3):453\u201362. https:\/\/doi.org\/10.1016\/j.bcp.2004.02.025.","journal-title":"Biochem Pharmacol"},{"issue":"7","key":"2890_CR23","doi-asserted-by":"publisher","first-page":"581","DOI":"10.2174\/138945009788680392","volume":"10","author":"W Du","year":"2009","unstructured":"Du W, Searle JS. The Rb pathway and cancer therapeutics. Curr Drug Targets. 2009;10(7):581\u20139. https:\/\/doi.org\/10.2174\/138945009788680392.","journal-title":"Curr Drug Targets"},{"issue":"5","key":"2890_CR24","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1038\/s41418-022-00988-z","volume":"29","author":"K Engeland","year":"2022","unstructured":"Engeland K. Cell cycle regulation: p53\u2013p21-RB signaling. Cell Death Differ. 2022;29(5):946\u201360. https:\/\/doi.org\/10.1038\/s41418-022-00988-z.","journal-title":"Cell Death Differ"},{"issue":"10","key":"2890_CR25","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1021\/ml400093y","volume":"4","author":"LC Wu","year":"2013","unstructured":"Wu LC, Wen ZS, Qiu YT, Chen XQ, Chen HB, Wei MM, Liu Z, Jiang S, Zhou GB. Largazole arrests cell cycle at G1 phase and triggers proteasomal degradation of E2F1 in lung cancer cells. ACS Med Chem Lett. 2013;4(10):921\u20136. https:\/\/doi.org\/10.1021\/ml400093y.","journal-title":"ACS Med Chem Lett"},{"key":"2890_CR26","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12935-018-0511-5","volume":"18","author":"L Jiang","year":"2018","unstructured":"Jiang L, Wang Y, Liu G, Liu H, Zhu F, Ji H, Li B. C-Phycocyanin exerts anti-cancer effects via the MAPK signaling pathway in MDA-MB-231 cells. Cancer Cell Int. 2018;18:12. https:\/\/doi.org\/10.1186\/s12935-018-0511-5.","journal-title":"Cancer Cell Int"},{"issue":"1","key":"2890_CR27","doi-asserted-by":"publisher","first-page":"9474","DOI":"10.1038\/s41598-019-45905-6","volume":"9","author":"M Safaei","year":"2019","unstructured":"Safaei M, Maleki H, Soleimanpour H, Norouzy A, Zahiri HS, Vali H, Noghabi KA. Development of a novel method for the purification of C-phycocyanin pigment from a local cyanobacterial strain Limnothrix sp. NS01 and evaluation of its anticancer properties. Sci Rep. 2019;9(1):9474. https:\/\/doi.org\/10.1038\/s41598-019-45905-6.","journal-title":"Sci Rep"},{"key":"2890_CR28","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.chemphyslip.2014.04.001","volume":"181","author":"K Cosentino","year":"2014","unstructured":"Cosentino K, Garcia-Saez AJ. Mitochondrial alterations in apoptosis. Chem Phys Lipids. 2014;181:62\u201375. https:\/\/doi.org\/10.1016\/j.chemphyslip.2014.04.001.","journal-title":"Chem Phys Lipids"},{"issue":"6","key":"2890_CR29","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1038\/bjc.2015.85","volume":"112","author":"J Lopez","year":"2015","unstructured":"Lopez J, Tait SW. Mitochondrial apoptosis: killing cancer using the enemy within. Br J Cancer. 2015;112(6):957\u201362. https:\/\/doi.org\/10.1038\/bjc.2015.85.","journal-title":"Br J Cancer"},{"key":"2890_CR30","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1007\/s10811-017-1122-6","volume":"29","author":"P Vor\u00e1\u010dov\u00e1","year":"2017","unstructured":"Vor\u00e1\u010dov\u00e1 P, Vickov\u00e1 H. Screening of cyanobacterial extracts for apoptotic inducers: a combined approach of caspase-3\/7 homogeneous assay and time-lapse microscopy. J Appl Phycol. 2017;29:1933\u201343. https:\/\/doi.org\/10.1007\/s10811-017-1122-6.","journal-title":"J Appl Phycol"},{"issue":"6","key":"2890_CR31","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/sj.cdd.4401231","volume":"10","author":"E Gottlieb","year":"2003","unstructured":"Gottlieb E, Armour SM, Harris MH, Thompson CB. Mitochondrial membrane potential regulates matrix configuration and cytochrome c release during apoptosis. Cell Death Differ. 2003;10(6):709\u201317. https:\/\/doi.org\/10.1038\/sj.cdd.4401231.","journal-title":"Cell Death Differ"},{"key":"2890_CR32","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA120.014479","volume":"296","author":"M Mashimo","year":"2021","unstructured":"Mashimo M, Onishi M, Uno A, Tanimichi A, Nobeyama A, Mori M, Yamada S, Negi S, Bu X, Kato J, Moss J, Sanada N, Kizu R, Fujii T. The 89-kDa PARP1 cleavage fragment serves as a cytoplasmic PAR carrier to induce AIF-mediated apoptosis. J Biol Chem. 2021;296: 100046. https:\/\/doi.org\/10.1074\/jbc.RA120.014479.","journal-title":"J Biol Chem"},{"issue":"18","key":"2890_CR33","volume":"68","author":"R Heisman","year":"2022","unstructured":"Heisman R, Keithellakpam OS, Kshetrimayum V, Mukherjee PK, Sharma N. Phycocyanin purified from Westiellopsis sp. induces caspase 3 mediated apoptosis in breast cancer cell line MDA-MB-231. Algal Res. 2022;68(18): 102852.","journal-title":"Algal Res"},{"key":"2890_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.964816","volume":"12","author":"HK Permatasari","year":"2022","unstructured":"Permatasari HK, Wewengkang DS, Tertiana NI, Muslim FZ, Yusuf M, Baliulina SO, Daud VPA, Setiawan AA, Nurkolis F. Anti-cancer properties of Caulerpa racemosa by altering expression of Bcl-2, BAX, cleaved caspase 3 and apoptosis in HeLa cancer cell culture. Front Oncol. 2022;12: 964816. https:\/\/doi.org\/10.3389\/fonc.2022.964816.","journal-title":"Front Oncol"},{"issue":"2","key":"2890_CR35","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1039\/d4ob01395f","volume":"23","author":"K Delawska","year":"2025","unstructured":"Delawska K, Hajek J, Voracova K, Kuzma M, Mares J, Vickova K, Kadek A, Tuckova D, Gallob F, Divoka P, Moos M, Opekar S, Koch L, Saurav K, Sedlak D, Novak P, Urajova P, Dean J, Gazak R, Niedermeyer TJH, Kamenik Z, Simek P, Villunger A, Hrouzek P. Discovery of nostatin A, an azole-containing proteusin with prominent cytostatic and pro-apoptotic activity. Org Biomol Chem. 2025;23(2):449\u201360. https:\/\/doi.org\/10.1039\/d4ob01395f.","journal-title":"Org Biomol Chem"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02890-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-02890-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02890-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T12:46:29Z","timestamp":1757249189000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-02890-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,17]]},"references-count":35,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["2890"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-02890-3","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,17]]},"assertion":[{"value":"9 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"341"}}